CBD FOR PAIN : WHAT DOES THE SCIENCE SAY ? A new book by three distinguished scientists reviews the current status of CBD as a treatment for acute and chronic illness. By Linda A. Parker, Erin M. Rock, and Raphael Mechoulam on October 04, 2022 Excerpted from CBD: What Does the Science Say ? by Linda A. Parker, Erin M. Rock, and Raphael Mechoulam, published by MIT Press (2022, 309 pp.). A large proportion of medicinal cannabis patients are using cannabis to treat pain syndromes, particularly for chronic pain alleviation. Cannabis use for unmanageable pain has been shown to reduce the dose of opiates [...]
Lire la suiteCannabinoid-based Medications for Pain Raymond M. St. Marie, MD; Raphael J. Leo, MA, MD Current Psychiatry, 2021, 20(5), 21-33. Abstract and Introduction Introduction Against the backdrop of an increasing opioid use epidemic and a marked acceleration of prescription opioid–related deaths,[1,2] there has been an impetus to explore the usefulness of alternative and co-analgesic agents to assist patients with chronic pain. Preclinical studies employing animal-based models of human pain syndromes have demonstrated that cannabis and chemicals derived from cannabis extracts may mitigate several pain conditions.[3] Because there are significant comorbidities between psychiatric disorders and chronic pain, psychiatrists are likely to care for patients with chronic pain. As [...]
Lire la suiteBibliographie : Kétamine Dr Christian Sueur, GRECC, (mai 2021) Kétamine en Psychiatrie : 1 - 3 Usages thérapeutiques en médecine psychédélique : 4 Kétamine et psychose : 5 - 6 Kétamine et traitement de la dépression : 7 - 20 Kétamine et prise en charge de l’idéation suicidaire : 21 - 22 Kétamine et traitement de la dépression chez les enfants et adolescents : 23 - 24 Kétamine et prise en charge des troubles psychotraumatiques (PTSD) : 25 - 27 Ketamine et addictions : 28 - 29 Kétamine et sevrage des opiacés : 30 Kétamine et prise en charge de la douleur : 31 - 32 Kétamine et prise en charge de [...]
Lire la suiteCannabinoids Promising for Improving Appetite, Behavior in Dementia Pauline Anderson Medscape Medical News © March 19, 2021 For patients with dementia, cannabinoids may be a promising intervention for treating neuropsychiatric symptoms (NPS) and the refusing of food, new research suggests. Results of a systematic literature review showed that cannabinoids were associated with reduced agitation, longer sleep, and lower NPS. They were also linked to increased meal consumption and weight gain. Refusing food is a common problem for patients with dementia, often resulting in worsening sleep, agitation, and mood, study investigator Niraj Asthana, MD, a second-year resident in the Department of Psychiatry, University of California, San Diego, told [...]
Lire la suiteThe Impact of Cannabidiol on Psychiatric and Medical Conditions Thersilla Oberbarnscheidt, Norman S. Miller Journal of Clinical and Medical Research, 2020, 12, (7), 393-403. Doi : 10.14740/jocmr4159 Abstract Cannabidiol (CBD) is a substance chemically derived from Cannabis sativa and discussed to be non-psychoactive. According to the FDA, marijuana is classified as a schedule I substance; however, hemp which is defined as extracts from marijuana including cannabinoids containing less than 0.3% tetrahydrocannabinol (THC), is excluded from that controlled substance act and available at local convenience stores in the US as it is seen as an herbal supplement. CBD is purported to be used for various medical [...]
Lire la suiteCannabis for Pain? An Expert's Guidance John Watson Medscape Neurology © 2021 WebMD, LLC January 05, 2021 Mark Steven Wallace, MD Many have put forth medical cannabis as a promising treatment for chronic pain that can potentially replace opioids. However, although it's never been easier for patients to access medical cannabis, those researching its use say that the structural challenges inherent to studying a Schedule 1 drug remain formidable. Medscape recently spoke with Mark Steven Wallace, MD, a pain management specialist and chair of the Division of Pain Medicine at UC San Diego Health, about the latest data on medical cannabis and the challenges in studying its clinical use in pain [...]
Lire la suiteCannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand Graham Gulbransen, MBChB, FAChAM, FRNZCGP1*, William Xu2, Bruce Arroll, MBChB, PhD, FRNZCG BJGP Open, 2020, 1-8 DOI : 10.3399/bjgpopen20X101010 Abstract Background : Cannabidiol (CBD) is the non- euphoriant component of cannabis. In 2017, the New Zealand Misuse of Drugs Regulations (1977) were amended, allowing doctors to prescribe CBD. Therapeutic benefit and tolerability of CBD remains unclear. Aim : To review the changes in self- reported quality of life measurements, drug tolerability, and dose- dependent relationships in patients prescribed CBD oil for various conditions at a single institution. Design & setting : An [...]
Lire la suiteCancer, Cannabis, and the Search for Relief Marcin Chwistek JNCCN—Journal of the National Comprehensive Cancer Network, 2019, Volume 17, Issue 9, 1142-1144. doi : 10.6004/jnccn.2019.7347 “How about medical marijuana?” is a common and often challenging question in oncology clinics today. It is easy to see why. Answering the question is fraught with clinical, legal, and administrative uncertainties. We all want to give patients the best advice, but not much about medical cannabis seems straightforward today. Whatever answer we provide can feel unsatisfactory to patients or ourselves. Answering clinical questions through high-quality research will take many years. And significant political power will be needed to [...]
Lire la suiteA low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers Johannes G. Ramaekers, Nadia Hutten, Natasha L. Mason, Patrick Dolder1, Eef L. Theunissen, Friederike Holze, Matthias E. Liechti, Amanda Feilding and Kim P.C. Kuypers Journal of Psychopharmacology, 2020, 1–8. doi : 10.1177/026988112094093 Abstract Background : Lysergic acid diethylamide (LSD) is an ergot alkaloid derivative with psychedelic properties that has been implicated in the management of persistent pain. Clinical studies in the 1960s and 1970s have demonstrated profound analgesic effects of full doses of LSD in terminally ill patients, but this line of research evaporated after LSD was scheduled worldwide. Aim : The present [...]
Lire la suiteCannabis Misconceptions Still Common Among MS Clinicians Nancy Melville June 05, 2020 https://www.medscape.com/viewarticle/931872?nlid=135873_425&src=WNL_mdplsfeat_200609_mscpedit_psyc&uac=292598PZ&spon=12&impID=2413707&faf=1 Despite the ever-increasing acceptance of medical cannabis and its notably common use in patients with multiple sclerosis (MS), clinicians treating those patients still may be poorly informed about risks, benefits, regulations, and proper uses, experts say. "There is evidence of a 'clinical void,' with clinicians on one side and people with MS and other conditions on the other that doesn't usually exist regarding therapies that people with MS are using," said Allen C. Bowling, MD, PhD, director of the NeuroHealth Institute and clinical professor of neurology at the University of Colorado, in Aurora. His [...]
Lire la suite